NEW YORK – Commercial lab company OmniSeq on Thursday announced that it is collaborating with the University of Pittsburgh Medical Center (UPMC) on a Phase II clinical trial of immunotherapy in head and neck cancer.
NEW YORK – Commercial lab company OmniSeq on Thursday announced that it is collaborating with the University of Pittsburgh Medical Center (UPMC) on a Phase II clinical trial of immunotherapy in head and neck cancer.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.